NCT07216105 - FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

113

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2030

Conditions

Non-Small Cell Lung CancerColorectal CancerBreast CancerOvarian CancerEndometrial CarcinomaHead and Neck Squamous Cell Carcinoma

Interventions

DRUG

FT836

FT836 drug product is administered as an intravenous infusion on multiple days schedule at treatment cycle.

DRUG

Paclitaxel

IV infusion ; 80 mg/m2 QW; Days -21, -14, and -7

DRUG

Cetuximab

Cetuximab administration will begin on Day -4 at the recommended initial dose of 400 mg/m2 as a 120-minute IV infusion

DRUG

Trastuzumab

trastuzumab administration will begin on Day -4 at an initial dose of 4 mg/kg as a 90-minute IV infusion.

Trial Locations (1)

RECRUITING

University of Minnesota Masonic Cancer Center, Minneapolis